Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.

Li YM, Zhang LH, Li XJ, Zhang B, Hou JN, Tong NW

Diabetes therapy : research, treatment and education of diabetes and related disorders26 Mar 2020Cited by 3 (Europe PMC)

PMID32219675PMCIDPMC7192982DOI10.1007/s13300-020-00799-wPepBankPUB-32219675

Read at source PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialMechanism
In OAM-naïve Chinese patients with T2D, dulaglutide groups had increased beta cell function compared with glimepiride.
In plain wordsIn Chinese patients with diabetes, dulaglutide improved insulin-producing cell function more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBeta cell function
Study
n = 264
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Beta cell function was significantly increased for dulaglutide groups compared to glimepiride.
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967505
02HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients with T2D, dulaglutide 0.75 mg reduced HbA1c by 1.84% versus 1.37% with glimepiride.
In plain wordsIn Chinese patients with diabetes, dulaglutide 0.75 mg lowered HbA1c more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n = 177
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change from baseline
−1.84%
dulaglutide 0.75 mg
HbA1c change from baseline
−1.37%
glimepiride
Source sentences
Summary
A greater glycated hemoglobin (HbA1c) reduction from baseline was observed with dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (- 2.02% and - 1.84% vs - 1.37%, respectively; both P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967502
03HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients, HbA1c below 7.0% occurred in 81.1% with dulaglutide 0.75 mg versus 65.5% with glimepiride.
In plain wordsIn Chinese patients, more reached the HbA1c target with dulaglutide 0.75 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c target attainment
Study
n = 177
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c <7.0% attainment
81.1%
dulaglutide 0.75 mg
HbA1c <7.0% attainment
65.5%
glimepiride
Source sentences
Summary
Significantly more patients in dulaglutide 1.5 mg and 0.75 mg groups achieved HbA1c targets < 7.0% compared to glimepiride (86.2% and 81.1% vs 65.5%; P = 0.002 and P = 0.026, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967504
04HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients, weight changed by -0.96 kg with dulaglutide 0.75 mg versus +0.73 kg with glimepiride.
In plain wordsIn Chinese patients, dulaglutide 0.75 mg reduced weight compared with weight gain on glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 177
Comparator
Glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
Body weight change
−0.96 kg
dulaglutide 0.75 mg
Body weight change
0.73 kg
glimepiride
Source sentences
Summary
Mean body weight was significantly reduced for dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (- 1.40 kg and - 0.96 kg vs + 0.73 kg, respectively; both P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967507
05HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients with T2D, dulaglutide 1.5 mg reduced HbA1c by 2.02% versus 1.37% with glimepiride.
In plain wordsIn Chinese patients with diabetes, dulaglutide 1.5 mg lowered HbA1c more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n = 174
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change from baseline
−2.02%
dulaglutide 1.5 mg
HbA1c change from baseline
−1.37%
glimepiride
Source sentences
Summary
A greater glycated hemoglobin (HbA1c) reduction from baseline was observed with dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (- 2.02% and - 1.84% vs - 1.37%, respectively; both P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967501
06HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients, HbA1c below 7.0% occurred in 86.2% with dulaglutide 1.5 mg versus 65.5% with glimepiride.
In plain wordsIn Chinese patients, more reached the HbA1c target with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c target attainment
Study
n = 174
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c <7.0% attainment
86.2%
dulaglutide 1.5 mg
HbA1c <7.0% attainment
65.5%
glimepiride
Source sentences
Summary
Significantly more patients in dulaglutide 1.5 mg and 0.75 mg groups achieved HbA1c targets < 7.0% compared to glimepiride (86.2% and 81.1% vs 65.5%; P = 0.002 and P = 0.026, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967503
07HumanRandomized controlled trialEfficacy outcome
In OAM-naïve Chinese patients, weight changed by -1.40 kg with dulaglutide 1.5 mg versus +0.73 kg with glimepiride.
In plain wordsIn Chinese patients, dulaglutide 1.5 mg reduced weight compared with weight gain on glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 174
Comparator
Glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
Body weight change
−1.4 kg
dulaglutide 1.5 mg
Body weight change
0.73 kg
glimepiride
Source sentences
Summary
Mean body weight was significantly reduced for dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (- 1.40 kg and - 0.96 kg vs + 0.73 kg, respectively; both P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, n = 87; dulaglutide 0.75 mg, n = 90; glimepiride, n = 87).
Summary · context
AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1-3 mg/day).
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967506
08HumanRandomized controlled trialSafety outcome
In OAM-naïve Chinese patients, hypoglycemia occurred in 7.9% with dulaglutide 1.5 mg versus 18.2% with glimepiride.
In plain wordsIn Chinese patients, low blood sugar occurred less often with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Measurements
Hypoglycemia incidence
7.9%
dulaglutide 1.5 mg
Hypoglycemia incidence
18.2%
glimepiride
Source sentences
Summary
Through 26 weeks, 7.9%, 4.2%, and 18.2% of patients reported hypoglycemia, and 40.4%, 23.2%, and 8.0% of patients reported at least one gastrointestinal treatment emergent adverse event, in dulaglutide 1.5 mg, 0.75 mg, and glimepiride groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the AWARD-CHN1 study compared the efficacy and safety of once-weekly dulaglutide with glimepiride in oral antihyperglycemic medication (OAM)-naïve Chinese patients with T2D.
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967508
09HumanRandomized controlled trialSafety outcome
In OAM-naïve Chinese patients, hypoglycemia occurred in 4.2% with dulaglutide 0.75 mg versus 18.2% with glimepiride.
In plain wordsIn Chinese patients, low blood sugar occurred less often with dulaglutide 0.75 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg weekly · 26 weeksAs given in this study (human).
Measurements
Hypoglycemia incidence
4.2%
dulaglutide 0.75 mg
Hypoglycemia incidence
18.2%
glimepiride
Source sentences
Summary
Through 26 weeks, 7.9%, 4.2%, and 18.2% of patients reported hypoglycemia, and 40.4%, 23.2%, and 8.0% of patients reported at least one gastrointestinal treatment emergent adverse event, in dulaglutide 1.5 mg, 0.75 mg, and glimepiride groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the AWARD-CHN1 study compared the efficacy and safety of once-weekly dulaglutide with glimepiride in oral antihyperglycemic medication (OAM)-naïve Chinese patients with T2D.
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967509
10HumanRandomized controlled trialSafety outcome
In OAM-naïve Chinese patients, gastrointestinal adverse events occurred in 40.4% with dulaglutide 1.5 mg versus 8.0% with glimepiride.
In plain wordsIn Chinese patients, digestive side effects occurred more often with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGastrointestinal treatment emergent adverse events
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Measurements
Gastrointestinal treatment emergent adverse events incidence
40.4%
dulaglutide 1.5 mg
Gastrointestinal treatment emergent adverse events incidence
8%
glimepiride
Source sentences
Summary
Through 26 weeks, 7.9%, 4.2%, and 18.2% of patients reported hypoglycemia, and 40.4%, 23.2%, and 8.0% of patients reported at least one gastrointestinal treatment emergent adverse event, in dulaglutide 1.5 mg, 0.75 mg, and glimepiride groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the AWARD-CHN1 study compared the efficacy and safety of once-weekly dulaglutide with glimepiride in oral antihyperglycemic medication (OAM)-naïve Chinese patients with T2D.
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967510
11HumanRandomized controlled trialSafety outcome
In OAM-naïve Chinese patients, gastrointestinal adverse events occurred in 23.2% with dulaglutide 0.75 mg versus 8.0% with glimepiride.
In plain wordsIn Chinese patients, digestive side effects occurred more often with dulaglutide 0.75 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGastrointestinal treatment emergent adverse events
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly · 26 weeksAs given in this study (human).
Measurements
Gastrointestinal treatment emergent adverse events incidence
23.2%
dulaglutide 0.75 mg
Gastrointestinal treatment emergent adverse events incidence
8%
glimepiride
Source sentences
Summary
Through 26 weeks, 7.9%, 4.2%, and 18.2% of patients reported hypoglycemia, and 40.4%, 23.2%, and 8.0% of patients reported at least one gastrointestinal treatment emergent adverse event, in dulaglutide 1.5 mg, 0.75 mg, and glimepiride groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the AWARD-CHN1 study compared the efficacy and safety of once-weekly dulaglutide with glimepiride in oral antihyperglycemic medication (OAM)-naïve Chinese patients with T2D.
Summary · context
This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.
Report a problemFND-3221967511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01644500

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 737Jul 2012 to Aug 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.